GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (OTCPK:NONOF) » Definitions » Beneish M-Score
中文

Novo Nordisk A/S (Novo Nordisk A/S) Beneish M-Score

: -2.58 (As of Today)
View and export this data going back to . Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.58 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Novo Nordisk A/S's Beneish M-Score or its related term are showing as below:

NONOF' s Beneish M-Score Range Over the Past 10 Years
Min: -3.03   Med: -2.6   Max: -2.16
Current: -2.58

During the past 13 years, the highest Beneish M-Score of Novo Nordisk A/S was -2.16. The lowest was -3.03. And the median was -2.60.


Novo Nordisk A/S Beneish M-Score Historical Data

The historical data trend for Novo Nordisk A/S's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.66 -2.31 -2.16 -2.74 -2.58

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.74 -2.68 -2.46 -2.77 -2.58

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Beneish M-Score falls into.



Novo Nordisk A/S Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Novo Nordisk A/S for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9998+0.528 * 0.9918+0.404 * 0.9692+0.892 * 1.345+0.115 * 1.0608
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9266+4.679 * -0.07823-0.327 * 1.0044
=-2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $11,011 Mil.
Revenue was 9636.42 + 8404.911 + 7901.745 + 7676.275 = $33,619 Mil.
Gross Profit was 8171.271 + 7014.898 + 6758.538 + 6499.381 = $28,444 Mil.
Total Current Assets was $20,432 Mil.
Total Assets was $46,012 Mil.
Property, Plant and Equipment(Net PPE) was $13,309 Mil.
Depreciation, Depletion and Amortization(DDA) was $1,363 Mil.
Selling, General, & Admin. Expense(SGA) was $8,922 Mil.
Total Current Liabilities was $24,822 Mil.
Long-Term Debt & Capital Lease Obligation was $3,003 Mil.
Net Income was 3213.408 + 3216.795 + 2827.166 + 2850.033 = $12,107 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was 1397.407 + 5862.587 + 4158.53 + 4288.427 = $15,707 Mil.
Total Receivables was $8,188 Mil.
Revenue was 6847.883 + 6061.727 + 5861.006 + 6224.509 = $24,995 Mil.
Gross Profit was 5671.446 + 5103.898 + 4999.006 + 5200.148 = $20,974 Mil.
Total Current Assets was $15,406 Mil.
Total Assets was $34,353 Mil.
Property, Plant and Equipment(Net PPE) was $9,493 Mil.
Depreciation, Depletion and Amortization(DDA) was $1,038 Mil.
Selling, General, & Admin. Expense(SGA) was $7,158 Mil.
Total Current Liabilities was $17,221 Mil.
Long-Term Debt & Capital Lease Obligation was $3,463 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(11011.441 / 33619.351) / (8188.213 / 24995.125)
=0.327533 / 0.327592
=0.9998

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(20974.498 / 24995.125) / (28444.088 / 33619.351)
=0.839144 / 0.846063
=0.9918

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (20431.615 + 13308.509) / 46012.466) / (1 - (15405.886 + 9493.372) / 34352.903)
=0.266718 / 0.275192
=0.9692

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=33619.351 / 24995.125
=1.345

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1038.005 / (1038.005 + 9493.372)) / (1363.166 / (1363.166 + 13308.509))
=0.098563 / 0.092911
=1.0608

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(8921.859 / 33619.351) / (7158.307 / 24995.125)
=0.265379 / 0.286388
=0.9266

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3003.453 + 24822.233) / 46012.466) / ((3462.672 + 17220.806) / 34352.903)
=0.604742 / 0.602088
=1.0044

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(12107.402 - 0 - 15706.951) / 46012.466
=-0.07823

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Novo Nordisk A/S has a M-score of -2.54 suggests that the company is unlikely to be a manipulator.


Novo Nordisk A/S Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.